



PUF VENTURES INC.

NEWS RELEASE

Solaris Nutraceuticals Receives AUD\$2,500,000 Grant from Federal Department of Innovation, Industry & Science

Vancouver, British Columbia / Sydney, New South Wales / February 15, 2018 – PUF Ventures Inc. (“PUF” or the “Company”) (CSE: PUF) (Frankfurt: PU3) (OTCPK: PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, and its strategic partner MYM Nutraceuticals (CSE: MYM) are pleased to announce the Casino, New South Wales based Solaris Nutraceuticals Pty Ltd, which is building the largest medical cannabis greenhouse southern hemisphere, has been awarded a AUD\$2,500,000 Regional Jobs Investment Program (RJIP) grant, through Federal Department of Innovation, Industry & Science,

“We are co-investing with Solaris Nutraceuticals to make sure it (the medicinal cannabis facility) happens,” said Kevin Hogan, Australian Member of Parliament. “Up to 280 jobs will be there one day providing this great new product that is needed by our community. We look forward to having the largest medicinal cannabis facility in the Southern Hemisphere soon in Casino.”

“We are very honoured to be awarded this Federal Grant towards the construction of our 1,200,000 sq.-ft greenhouse,” said Michael Horsfall, Co-founder and CEO of Solaris Nutraceuticals. “We have been overwhelmed with the generous support we have received from all levels of government. We are working hard to deliver this project. We expect to create upwards of 300 to 500 direct and indirect jobs in the Northern Rivers Region from our greenhouse project. This will provide a significant boost to the local economy”

The new facility will be Australia’s largest growing, manufacturing, processing and research facility in Australia. This is an innovative project which will help patients, create new jobs, complete further research and develop new products in the medical cannabis field.

The company is currently in the assessment stage for three licenses with the Office of Drug Control in Canberra.

Kevin Hogan, Member of Parliament: https://m.facebook.com/story.php?story_fbid=1694316460660111&id=356113427813761&refsrc=http%3A%2F%2Ft.co%2F4LMgCG1HkD&_rdr

About Solaris Nutraceuticals Inc.

Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. The Company is owned by PUF Ventures Inc. (CSE: PUF), MYM Nutraceuticals Inc. (CSE: MYM), Chrome Holdings of Australia and private investors. It has submitted applications and plans with Australia’s Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia. Solaris’ corporate mission is to deliver environmentally friendly, sun grown medicinal grade cannabis and to develop medicines and treatments for pain management and other medical

conditions. The company's focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients. For more information, visit www.solarisnutraceuticals.com.

About PUF Ventures Inc.

PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., a private Ontario company and advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.

ON BEHALF OF THE BOARD OF DIRECTORS

Derek Ivany
President & CEO

For additional information:

PUF Ventures Inc.

E: ir@puf.ca
T: (800) 783-6056

Solaris Nutraceuticals

Michael Horsfall
President & CEO
E: michael@solarisnutraceuticals.com
T: +61 417 041 272

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.